Gilead Sciences | GILD - Fremdkapital

Aktienkurs
129.58
Täglich Wechseln
-2.48 -1.88%
Monatlich
-6.47%
Jährlich
26.42%
Q2 Prognose
126.98




Fremdkapital Veränderung Datum
AbbVie USD 58.94B 4.03B 2025-12
Agios Pharmaceuticals USD 1.06M 0 2022-09
ALKERMES USD 1.48B 1.2B 2026-03
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Amgen USD 51.89B 1.88B 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Glaxosmithkline GBP 19.82B 203.13M 2025-12
Incyte USD 29.41M 785K 2026-03
J&J USD 37.53B 1.91B 2026-03
Merck USD 46.67B 77M 2026-03
Moderna USD 603M 7M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 286.94M 1.74B 2026-03
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 13.84B 1.88B 2026-03
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
United Therapeutics USD 100M 100M 2024-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12